Resultados de procura - Meredith Libeg

  • Mostrando 1 - 3 Resultados de 3
Limitar resultados
  1. 1
    FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

    FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy por Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal, Sirisha L. Mushti, Kun He, Meredith Libeg, Patricia Keegan, Richard Pazdur

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy

    Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy por Dickran Kazandjian, Sean Khozin, Gideon M. Blumenthal, Lijun Zhang, Shenghui Tang, Meredith Libeg, Paul G. Kluetz, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma

    FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma por Julia A. Beaver, Marc R. Theoret, Sirisha L. Mushti, Kun He, Meredith Libeg, Kirsten B. Goldberg, Rajeshwari Sridhara, Amy E. McKee, Patricia Keegan, Richard Pazdur

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: